Artiva Biotherapeutics to Present Preclinical Data for AB-201, a HER2-Targeting CAR-NK Cell Therapy, at SITC 36th Annual Meeting
- Company to present preclinical data for AB-201, an anti-HER2-specific CAR-NK cell therapy candidate developed with Artiva’s AlloNKTM Platform
- Data highlight scaled production and anti-tumor activity in support of clinical development for the treatment of HER2+ solid tumors
SAN DIEGO, October 21, 2021 – Artiva Biotherapeutics, Inc., (“Artiva”) an oncology company focused on developing and commercializing off-the-shelf, allogeneic natural killer (NK) cell-based therapies to treat cancer, today announced an upcoming presentation describing AB-201, an anti-HER2 CAR-NK cell therapy candidate, at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting and Pre-Conference Programs to be held November 10-14, 2021, virtually and in-person at the Walter E. Washington Convention Center in Washington, D.C.
The full abstract is scheduled to be available on the SITC website on November 9, 2021.
Poster Presentation Info:
- Title: Development of AB-201, a novel allogeneic anti-HER2-specific CAR-NK cell therapy for the treatment of HER2+ tumors
- Abstract Number: #129
- Date: November 12 – 13, 2021
- Time: 7:00 am – 8:30 pm ET
- Location: Hall E
About HER2+ Solid Tumors
HER2 is a receptor tyrosine kinase that is overexpressed on many solid tumors, including breast, gastric, and bladder cancers. It is estimated that there are over 50,000 patients diagnosed annually in U.S. with tumors having high HER2 expression, with overexpression found in approximately 20% of breast cancer cases and in over 10% of bladder and gastric cancers. Currently, there are eight approved HER2-directed therapies including monoclonal antibodies, antibody-drug conjugates, and small molecule kinase inhibitors. While many patients with advanced HER2+ cancers derive meaningful benefit from HER2-targeted therapies, they typically progress beyond approved therapies, and treatment of these patients remains a large unmet medical need.
About AB-201
AB-201 is an allogeneic anti-HER2 CAR-NK cell therapy candidate manufactured from cord blood, containing a proprietary HER2 antigen recognition domain. Artiva is developing AB-201 for the treatment of HER2-overexpressing tumors, such as breast, gastric, and bladder cancers. The company is currently manufacturing AB-201 in large scale bioreactors, resulting in potentially thousands of doses of product from a single donor cord blood unit.
About Artiva Biotherapeutics
Artiva’s mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies that are safe and accessible to cancer patients. Artiva’s pipeline includes AB-101, an ADCC enhancer NK-cell therapy candidate for use in combination with monoclonal antibodies or innate-cell engagers. The company is currently advancing a Phase 1/2 clinical trial of AB-101 in combination with rituximab for the treatment of relapsed or refractory B-cell lymphomas. Artiva’s pipeline also includes AB-202, a CD19-specific CAR-NK cell therapy for the treatment of B-cell malignancies. The company has entered into therapeutic NK cell collaborations with Merck Sharp & Dohme Corp. and with Affimed GmbH. Artiva’s AlloNK™ platform incorporates cell expansion, activation, and engineering technology developed by the Company’s strategic partner, GC Cell Corporation, a member of the GC family of companies, a leading healthcare company in Korea. Artiva is headquartered in San Diego.
Contacts
Media: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com, +1.858.344.8091
Investors: Michael E. Faerm, Artiva Biotherapeutics, Inc., mfaerm@artivabio.com